{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"38.6","value":"3870"},{"groupId":"OG001","spread":"41.8","value":"1410"},{"groupId":"OG002","spread":"38.6","value":"2820"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"30"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received atezolizumab, 1800 mg, co-mixed with rHuPH20, as SC injection on Cycle 1 Day 1 (1 cycle=21 days), followed by atezolizumab, 1200 mg, as an IV infusion, Q3W on Day 1 of subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.","id":"OG000","title":"Part 1 Cohort 1: Atezolizumab SC Co-mix 1800 mg"},{"description":"Participants received atezolizumab, 1200 mg, co-mixed with rHuPH20, as SC injection, Q2W, on Day 1 of the first 3 cycles (Cycle 1-3=14 days), followed by atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.","id":"OG001","title":"Part 1 Cohort 2: Atezolizumab SC Co-mix 1200 mg"},{"description":"Participants received atezolizumab, 1800 mg, co-mixed with rHuPH20, as SC injection, Q3W, on Day 1 of first 3 cycles, followed by atezolizumab, 1200 mg, as an IV infusion, Q3W on Day 1 for subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.","id":"OG002","title":"Part 1 Cohort 3: Atezolizumab SC Co-mix 1800 mg"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK-evaluable population included all participants who received at least one dose of atezolizumab and had at least 1 evaluable post dose PK sample that could affect PK results. Overall number analyzed is the number of participants with data available for analysis.","reportingStatus":"POSTED","timeFrame":"Predose and up to 21 days post dose in Cycle 1 for cohorts 1 and 3 and from predose up to 14 days post last dose in Cycle 1 for cohort 2 (Cycle length= 21 days for cohorts 1 and 3 and 14 days for cohort 2)","title":"Part 1: Area Under the Concentration-time Curve (AUClast) of Atezolizumab","type":"SECONDARY","unitOfMeasure":"μg*day/mL"}